CTOs on the Move

Kinnate

www.kinnate.com

 
Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no approved targeted drugs and to overcome the limitations of marketed cancer therapies, such non-responsiveness or acquired and intrinsic resistance. Kinnate has two lead clinical programs being studied in solid tumors with RAF, NRAS and FGFR-driven alterations, and is rapidly progressing a pipeline of additional small molecule drug candidates as part of the Kinnate Discovery Engine.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.kinnate.com
  • 12830 El Camino Real Suite 150
    San Diego, CA USA 92130
  • Phone: 858.299.4699

Executives

Name Title Contact Details

Funding

Kinnate raised $74.5M on 12/19/2019
Kinnate raised $98M on 08/26/2020

Similar Companies

Standards Testing Laboratory

STL now operates the world's largest independent dynamic testing facility for tires, wheels and related automotive components, providing the rubber and automotive industries with dynamic laboratory testing, static and physical testing, fleet testing,

Bioanalytical Systems

BASi provides world-class research to the pharmaceutical industry worldwide. Established in 1974, we offer an extensive array of contract laboratory services and also manufacture more than 30 different scientific instruments. At BASi we focus on developing innovative services and products that increase efficiency and reduce costs associated with taking new drugs to market.

Abeona Therapeutics

Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company`s multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company`s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM™ Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a novel gene-corrected cell therapy poised to enter Phase 3 in mid-2019 and complemented by one-time gene therapy candidates across four lysosomal storage diseases. Several preclinical discoveries are led by an emerging program in cystic fibrosis that uses the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases.

twoXAR

twoXAR is an artificial intelligence-driven drug discovery company.

Ribometrix

Ribometrix is a platform therapeutics company discovering small molecule drugs that target functional 3D RNA structures to treat human diseases.